ArriVent BioPharma News

H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $25

H.C. Wainwright analyst Robert Burns maintains $ArriVent BioPharma(AVBP.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 24.0

Futu NewsJun 6 18:33

ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment

ArriVent BioPharma (AVBP) said Wednesday that it signed a collaboration agreement with Alphamab Oncology's Jiangsu Alphamab Biopharmaceuticals unit to discover, develop, and commercialize antibody dru

MT NewswiresJun 5 23:26

ArriBent BioPharma Has Collaborated With Jiangsu Alphamab Biopharmaceuticals, Alphamab Oncology's Subsidiary For Cancer-focused Antibody-drug Conjugates With Upfront And Potential Milestone Payments To Alphamab Of Up To $615.5M

ArriBent BioPharma Has Collaborated With Jiangsu Alphamab Biopharmaceuticals, Alphamab Oncology's Subsidiary For Cancer-focused Antibody-drug Conjugates With Upfront And Potential Milestone Payments T

BenzingaJun 5 19:09

Express News | Arrivent Announces a Multi-Target ADC Collaboration With Alphamab

BreakingsJun 5 19:00

Express News | On June 5, 2024, Concor Pharma-B (09966.HK) announced that its wholly-owned subsidiary, Jiangsu Kangning Jerry Biopharmaceutical Co., Ltd. (Kangning Jerry), has entered into a research and cooperation agreement with ArriVent BioPharma, Inc. (which is list

BreakingsJun 5 17:06

Express News | Alphamab Oncology - Collaboration With Arrivent for Research, Development and Commercialization of ADC Products

BreakingsJun 5 17:01

Buy Rating Affirmed for ArriVent BioPharma on Strong Drug Trial Prospects and Strategic Advancements

TipRanksMay 20 20:25

ArriVent BioPharma Welcomes Dr. Hohneker to Board

TipRanksMay 17 04:23

Press Release: ArriVent Appoints John Hohneker, M.D., to Its Board of Directors

ArriVent BioPharma today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics.

Dow JonesMay 17 04:05

The top four private equity firms revealed the “US stock report card”: Pinduoduo is still proud of Gao Yi and Gao Yi, but Jing Lin quietly reduced its positions

① The latest moves by Chinese private equity institutions such as Gao Yi, Gao Yi, Jing Lin, and Himalaya have recently been revealed; ② Overall, Chinese securities are still popular among Chinese institutions, especially Pinduoduo, and are also famous in the leading positions of Gao Yi, Gao Yi, and Jing Lin; ③ However, Jing Lin drastically reduced its holdings of Pinduo by 1.1 million shares in the first quarter, which is at odds with Gao Yu and Gao Yi's move to increase positions.

cls.cnMay 16 14:33

HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $25 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $25 price target.

BenzingaMay 9 19:14

Buy Rating for ArriVent BioPharma Amid Strong Financials and Promising Clinical Trials

TipRanksMay 9 18:36

Buy Rating Affirmed for ArriVent BioPharma on Strong Firmonernib Prospects and Financial Stability

TipRanksMay 9 03:55

Arrivent BioPharma (AVBP.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -0.70 dollars, previous value of -9.45 dollars, expected value of -1.05 dollars.

Arrivent BioPharma (AVBP.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -0.70 dollars, previous value of -9.45 dollars, expected value of -1.05 dollars.

Zhitong FinanceMay 8 20:50

ArriVent BioPharma Q1 EPS $(0.70) Beats $(1.05) Estimate

ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1.05) by 33.33 percent.

BenzingaMay 8 20:15

ArriVent BioPharma | 10-Q: Quarterly report

SEC announcementMay 8 20:03 · Announcements

ArriVent BioPharma Had Cash and Cash Equivalents of $317.4M as of March 31 >AVBP

ArriVent BioPharma Had Cash and Cash Equivalents of $317.4M as of March 31 >AVBP

Dow JonesMay 8 20:00

ArriVent BioPharma 1Q Loss $17.4M >AVBP

ArriVent BioPharma 1Q Loss $17.4M >AVBP

Dow JonesMay 8 20:00

ArriVent BioPharma 1Q Loss/Shr 70c >AVBP

ArriVent BioPharma 1Q Loss/Shr 70c >AVBP

Dow JonesMay 8 20:00

ArriVent BioPharma Initiated at Buy by HC Wainwright & Co.

ArriVent BioPharma Initiated at Buy by HC Wainwright & Co.

Dow JonesApr 30 18:22